Finanzen von Evommune Inc (EVMN)EVMNEvommune Inc

Evaluating the bottom line, Evommune, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -178.02%, provide a clear picture of how effectively EVMN converts its operational activities into shareholder value.

In the context of the broader market, EVMN competes directly with industry leaders such as ADCT and ELDN. With a market capitalization of $247.15M, it holds a leading position in the sector. When comparing efficiency, EVMN's gross margin of N/A stands against ADCT's 88.68% and ELDN's N/A. Such benchmarking helps identify whether Evommune, Inc. is trading at a premium or discount relative to its financial performance.

Evommune has reported zero revenue in the last three quarters of 2026, with a net income of -32,246,000 USD in Q2 2026. The gross margin has dropped to 0% in the last two quarters, indicating severe operational challenges.